8-K
IIOT-OXYS, Inc. (ITOX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934
Date of Report (Date of earliest event reported): April 7, 2022
IIOT-OXYS,
Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 000-50773 | 56-2415252 |
|---|---|---|
| (State or Other Jurisdiction | (Commission File | (I.R.S. Employer |
| of Incorporation) | Number) | Identification Number) |
| 705 Cambridge Street<br><br> <br>Cambridge, MA 02141 | ||
| --- | ||
| (Address of principal executive offices, including zip code) | ||
| (401) 307-3092 | ||
| --- | ||
| (Registrant’s telephone number,<br><br> <br>including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ . Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ . Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ . Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ . Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 | Entry into a Material Definitive Agreement. |
|---|
Amendment to Cambridge MedSpace PromissoryNote
On April 7, 2022, the board of directors of IIOT-OXYS, Inc., a Nevada corporation (the “Company”), approved Amendment No. 2 to the 5% Secured Promissory Note (the “Note”) with Cambridge MedSpace, LLC, a Massachusetts limited liability company (the “Lender”), dated April 6, 2022, pursuant to which the Note was amended to extend the maturity date to March 1, 2024 and all prior defaults were waived. The Lender is owned by shareholders of the Company, or their affiliates, including Clifford Emmons, our Chief Executive Officer, Interim Chief Financial Officer, and director.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IIOT-OXYS, Inc. | ||
|---|---|---|
| Date: April 13, 2022 | By: | /s/ Clifford L. Emmons |
| Clifford L. Emmons, Chief Executive Officer |
| 2 |
| --- |